Encompass Health Corporation
NYSE:EHCMedical - Care Facilities
-$1.95 today
- Market cap
- $13.24B
- Beta
- 0.59
- P/E (TTM)
- 15.9
- EPS (TTM)
- $6.14
- Dividend yield
- 0.76%
Volume 0.84M
Average 0.92M
EHC Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Encompass Health CorporationNYSE: EHC
Gross Margin · Q2 FY2026 · quarter ended Jun 2026
Gross margin widens to 44.5%
Gross margin was 44.5% in Q2 FY2026, up 1.5 pp from a year earlier. On a trailing-twelve-month basis it was 43.9%, up 1.5 pp year over year. Over 3 fiscal years it widened by 2.9 pp.
Context
- Gross margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 43.2%
- Year-over-year change
- +1.7pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 43.2% | +1.7pp |
| FY2024 | 2024-12-31 | 41.6% | +0.3pp |
| FY2023 | 2023-12-31 | 41.3% | +1.0pp |
| FY2022 | 2022-12-31 | 40.3% | -2.1pp |
| FY2021 | 2021-12-31 | 42.4% | — |
Gross Margin vs competitors
How EHC compares with its peers on the latest reported figures
- EHC's LTM Jun 2026 gross margin of 43.9% is the highest of the 9 companies compared; the peer median is 25.1%.
- Its year-over-year change of +1.5 pp is the 2nd highest of 9, against a peer median of -0.8 pp.
- Over three fiscal years its change of +2.9 pp compares with a peer median of +0.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 43.9% | +1.5 pp | +2.9 pp | |
| LTM Jun 2026 | 32.4% | -0.2 pp | +1.0 pp | |
| LTM Oct 2026 | 32.1% | -1.4 pp | +2.1 pp | |
| LTM Sep 2026 | 32.0% | -6.6 pp | +3.2 pp | |
| LTM Jun 2026 | 30.4% | -3.2 pp | -5.9 pp | |
| LTM Jun 2026 | 19.7% | +2.7 pp | +5.4 pp | |
| LTM Sep 2026 | 18.5% | -0.1 pp | -3.9 pp | |
| LTM Mar 2026 | 14.8% | +1.1 pp | +0.5 pp | |
| LTM Jun 2026 | 14.1% | -1.7 pp | -1.3 pp | |
| Peer median (excluding EHC) | 25.1% | -0.8 pp | +0.7 pp | |
Competitors are the stored peer set for EHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.01B | 4.35B | 4.8B | 5.37B | 5.94B |
| Cost of Revenue | 2.31B | 2.6B | 2.82B | 3.14B | 3.37B |
| Gross Profit | 1.7B | 1.75B | 1.98B | 2.23B | 2.56B |
| Gross Margin | 42.4% | 40.3% | 41.3% | 41.6% | 43.2% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 228.5M | 209M | 258M | 266.5M | 295.2M |
| Operating Expenses | 1.04B | 1.12B | 1.25B | 1.37B | 1.51B |
| Depreciation & Amortization | 219.6M | 243.6M | 273.9M | 299.6M | 327.9M |
| EBITDA | 888.9M | 870.1M | 1.02B | 1.19B | 1.4B |
| EBITDA Margin | 22.1% | 20.0% | 21.3% | 22.1% | 23.7% |
| Operating Income | 659.4M | 630.2M | 731.8M | 864.5M | 1.05B |
| Operating Margin | 16.4% | 14.5% | 15.2% | 16.1% | 17.7% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 164.3M | 175.7M | 143.5M | 137.4M | 123.2M |
| Other Income / Expenses | (154.4M) | (179.4M) | (124.6M) | (114.9M) | (100.1M) |
| Income Before Tax | 505M | 450.8M | 607.2M | 749.6M | 953M |
| Pre-Tax Margin | 12.6% | 10.4% | 12.6% | 14.0% | 16.1% |
| Income Tax Expense | 101.9M | 100.1M | 132.2M | 150.2M | 192.9M |
| Net Income | 412.2M | 271M | 352M | 455.7M | 566.2M |
| Net Margin | 10.3% | 6.2% | 7.3% | 8.5% | 9.5% |
| EPS (Basic) | 4.15 | 2.72 | 3.54 | 4.53 | 5.62 |
| EPS (Diluted) | 4.11 | 2.70 | 3.47 | 4.46 | 5.54 |
| Weighted Avg Shares | 99M | 99.2M | 99.5M | 99.9M | 100.5M |
| Weighted Avg Shares (Diluted) | 100.2M | 100.4M | 101.3M | 102.2M | 102.2M |
Encompass Health Corporation
NYSE:EHC
Intrinsic Alpha fair value
Locked
Current Price
$134.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.